Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Therapeutic Approach to Low-Grade Serous Ovarian Carcinoma: State of Art and Perspectives of Clinical Research
Angiolo Gadducci, Stefania Cosio
Cancers (2020) Vol. 12, Iss. 5, pp. 1336-1336
Open Access | Times Cited: 39

Showing 1-25 of 39 citing articles:

Heterogeneity and treatment landscape of ovarian carcinoma
Ana Veneziani, Eduardo González-Ochoa, Husam Alqaisi, et al.
Nature Reviews Clinical Oncology (2023) Vol. 20, Iss. 12, pp. 820-842
Closed Access | Times Cited: 65
Platinum-resistant ovarian cancer: From drug resistance mechanisms to liquid biopsy-based biomarkers for disease management
Mohammad Aslam Khan, Kunwar Somesh Vikramdeo, Sarabjeet Kour Sudan, et al.
Seminars in Cancer Biology (2021) Vol. 77, pp. 99-109
Open Access | Times Cited: 42
Case report: ex vivo tumor organoid drug testing identifies therapeutic options for stage IV ovarian carcinoma
Marwah Al-Aloosi, Amanda M. Prechtl, Payel Chatterjee, et al.
Frontiers in Oncology (2024) Vol. 13
Open Access | Times Cited: 5
Fertility Sparing Medical Management Options in Gynecologic Cancers
Ana Kouri, Janelle Darby
Current Treatment Options in Oncology (2025)
Open Access
Management of early-stage ovarian cancer: open questions and debated issues
Salutari, Emilia Giudice, E. Rapisarda, et al.
Critical Reviews in Oncology/Hematology (2025), pp. 104704-104704
Closed Access
BRAF Targeting Across Solid Tumors: Molecular Aspects and Clinical Applications
Hiba Mechahougui, James Gutmans, Roumaïssa Gouasmi, et al.
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 8, pp. 3757-3757
Open Access
The Role of Systematic Lymphadenectomy in Low-Grade Serous Ovarian Cancer: A Systematic Review and Meta-Analysis
Rosa Montero-Macías, Juan José Segura‐Sampedro, Pascal Rigolet, et al.
Cancers (2024) Vol. 16, Iss. 5, pp. 955-955
Open Access | Times Cited: 3
Novel Endocrine Therapeutic Opportunities for Estrogen Receptor-Positive Ovarian Cancer—What Can We Learn from Breast Cancer?
Tine Ottenbourgs, Els Van Nieuwenhuysen
Cancers (2024) Vol. 16, Iss. 10, pp. 1862-1862
Open Access | Times Cited: 3
The drug efficacy testing in 3D cultures platform identifies effective drugs for ovarian cancer patients
Emma Åkerlund, Greta Gudoitytė, Elisabeth Moussaud-Lamodière, et al.
npj Precision Oncology (2023) Vol. 7, Iss. 1
Open Access | Times Cited: 9
Patient-derived tumor models are attractive tools to repurpose drugs for ovarian cancer treatment: Pre-clinical updates
Magdalena Cybula, Magdalena Bieniasz
Oncotarget (2022) Vol. 13, Iss. 1, pp. 553-575
Open Access | Times Cited: 14
Novel Therapies in Gynecologic Cancer
Juan Francisco Grau-Béjar, Ana Oaknin, Casey W. Williamson, et al.
American Society of Clinical Oncology Educational Book (2022), Iss. 42, pp. 483-499
Open Access | Times Cited: 13
Hormone Receptors and Epithelial Ovarian Cancer: Recent Advances in Biology and Treatment Options
Fulvio Borella, Stefano Fucina, Luca Mangherini, et al.
Biomedicines (2023) Vol. 11, Iss. 8, pp. 2157-2157
Open Access | Times Cited: 7
miR-4461 Regulates the Proliferation and Metastasis of Ovarian Cancer Cells and Cisplatin Resistance
Lei Dou, Yi Zhang
Frontiers in Oncology (2021) Vol. 11
Open Access | Times Cited: 16
Complete response with combined BRAF and MEK inhibition in BRAF mutated advanced low-grade serous ovarian carcinoma
Bengt Tholander, Anthoula Koliadi, Johan Botling, et al.
Upsala Journal of Medical Sciences (2020) Vol. 125, Iss. 4, pp. 325-329
Open Access | Times Cited: 16
Low-grade serous epithelial ovarian cancer: a comprehensive review and update for radiologists
S Amante, Filipa Santos, Teresa Margarida Cunha
Insights into Imaging (2021) Vol. 12, Iss. 1
Open Access | Times Cited: 15
Impressive and durable clinical responses obtained with dabrafenib and trametinib in low-grade serous ovarian cancer harbouring a BRAF V600E mutation
Bárbara Lima, Miguel Henriques Abreu, Susana Sousa, et al.
Gynecologic Oncology Reports (2022) Vol. 40, pp. 100942-100942
Open Access | Times Cited: 10
Functional estrogen receptor signal transduction pathway activity and antihormonal therapy response in low‐grade ovarian carcinoma
Cynthia S. E. Hendrikse, Phyllis van der Ploeg, Nienke M. A. van de Kruis, et al.
Cancer (2023) Vol. 129, Iss. 9, pp. 1361-1371
Open Access | Times Cited: 5
Outcome and prognostic factors of low‑grade serous ovarian cancer: An observational retrospective study
Hamed Alhusaini, Ahmed Badran, Amal Al Juhani, et al.
Molecular and Clinical Oncology (2024) Vol. 21, Iss. 1
Open Access | Times Cited: 1
Drug-Resistant Epithelial Ovarian Cancer: Current and Future Perspectives
Megha Mehrotra, Pratham Phadte, Priti S. Shenoy, et al.
Advances in experimental medicine and biology (2024), pp. 65-96
Closed Access | Times Cited: 1
Ovarian Cancer: Molecular Classification and Targeted Therapy
Febina Ravindran, Bibha Choudhary
IntechOpen eBooks (2021)
Open Access | Times Cited: 9
Traditional Systemic Treatment Options in Advanced Low-Grade Serous Ovarian Cancer after Successful Cytoreduction: A Systematic Review and Meta-Analysis
Rosa Montero-Macías, Pascal Rigolet, Elie Mikhael, et al.
Cancers (2022) Vol. 14, Iss. 15, pp. 3681-3681
Open Access | Times Cited: 6
(In)Distinctive Role of Long Non-Coding RNAs in Common and Rare Ovarian Cancers
Maja Sabol, Jean Calleja‐Agius, Riccardo Di Fiore, et al.
Cancers (2021) Vol. 13, Iss. 20, pp. 5040-5040
Open Access | Times Cited: 6
Skin Metastasis of Low-Grade Ovarian Serous Carcinoma: A Case Report
Lauren M Ching, Benjamin A. Tran, Kristen L Russomanno, et al.
Cureus (2023)
Open Access | Times Cited: 2
Deciphering the Therapeutic Applications of Nanomedicine in Ovarian Cancer Therapy: An Overview
Pooja Mathur, Shailendra Bhatt, Suresh Kumar, et al.
Current Drug Delivery (2023) Vol. 21, Iss. 9, pp. 1180-1196
Closed Access | Times Cited: 2
High In Vitro and In Vivo Activity of BI-847325, a Dual MEK/Aurora Kinase Inhibitor, in Human Solid and Hematologic Cancer Models
Vincent Vuaroqueaux, Alexandra Musch, Anne-Lise Peille, et al.
Cancer Research Communications (2023) Vol. 3, Iss. 10, pp. 2170-2181
Open Access | Times Cited: 2
Page 1 - Next Page

Scroll to top